Cianna's nonradioactive, long-term breast tumor localization implant gets FDA OK

The Savi Scout tumor localization implant remains inactive until a surgeon activates the device during a surgical biopsy or lumpectomy. (Cianna Medical)

The FDA cleared Cianna Medical’s breast tumor localization system, the first device of its kind to be FDA-cleared for long-term use.

Cianna’s Savi Scout reflector is a nonradioactive implant for the wire-free localization of breast tumors. While imaging can turn up cancerous tissue, not all breast tumors can be felt through the skin. In these cases, a wire is inserted or a radioactive “seed” is implanted into the cancerous tissue to help doctors locate the tumor during surgery later.

There are no restrictions on how long the Scout device may remain in the body, giving physicians more flexibility in treatment plans. Patients with a radioactive implant must take precautions until their implant is removed, but patients implanted with the Scout may continue with their usual activities, the company said in a statement.

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.

RELATED: Dune Medical scores $12M to take MarginProbe beyond breast cancer

The 4-millimeter Scout implant doesn’t affect a patient’s ability to undergo an MRI scan and is inactive until it is activated during a lumpectomy or surgical biopsy, the company said.

The system uses radar technology to spot tumors with an accuracy of ±1 millimeter.

“Achieving this milestone significantly advances Cianna Medical’s mission to reduce the burden breast cancer treatment places on women and their families,” said CEO Jill Anderson in the statement. “I applaud the vision of all our physicians and health systems who are leading the way in offering a new standard of care in breast tumor localization.”